A Trial to Evaluate Efficacy and Safety of Maridebart Cafraglutide in Adults Living With Elevated Liver Fat and Obesity or Overweight
← catalyst calendarNCT07441252 · readout in 406 d
Sponsored by Amgen (industry) · AMGN — their whole pipeline →.
Phase
Phase 2
Status
Recruiting
Study type
Interventional
Design
Randomized · Double · Treatment
Enrollment
180estimated
Sites
23
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-03-05 | actual | When the study began enrolling |
| Primary completion | 2027-09-29 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2027-12-22 | estimated | The whole study's end, after follow-up |
| First posted | 2026-02-27 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-06-18 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Overweight or Obesity and Elevated Liver Fat
Interventions
- Drug: Maridebart cafraglutide — also filed as AMG 133
- Drug: Placebo
Primary outcomes
what the primary-completion date above is the date OFPercent Change from Baseline in Liver Fat Content by Magnetic Resonance Imaging Proton Density Fat Fraction (MRI-PDFF) at Week 52
measured Baseline and Week 52
Percent Change from Baseline in Body Weight at Week 52
measured Baseline and Week 52
Permalink · AMGN's whole pipeline · Catalyst calendar · Every registered study · What changed